Fisher & Paykel Healthcare Corporation Limited today announced its results for the first half of the 2021 financial year, which ended 30 September 2020.
Read more
Fisher & Paykel Healthcare Corporation Limited today announced its results for the full year ended 31 March 2021.
Fisher & Paykel Healthcare Corporation Limited today announced its results for the first half of the 2022 financial year.
Fisher & Paykel Healthcare Corporation Limited today announced its results for the half year ended 30 September 2016. Net profit after tax was up 26% for the half at a record NZ$78.2 million.
Fisher & Paykel Healthcare Corporation Limited today reported record net profit after tax of NZ$190.2 million for the year ended 31 March 2018, an increase of 12% over the previous year.
Fisher & Paykel Healthcare Corporation Limited today announced its results for the half year ended 30 September 2018. Net profit after tax was NZ$97.4 million, up 20%.
Fisher & Paykel Healthcare today announced a record result for the 2019 financial year, with net profit after tax up 10% to NZ$209.2 million.
Fisher & Paykel Healthcare Corporation Limited announced today its results for the full year ended 31 March 2020. Operating revenue was $1.26 billion, up 18% over last year.
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
The heating and humidifying of respiratory gases is crucial for intubated patients. Learn about humidification devices, including active and passive.
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment
The AIRVO 2 family enables the transition of Optiflow therapy across critical, non-critical areas of the hospital and into the home.
Humidification for patients using a mask at home
Humidification for patients with a tracheostomy at home
Our newest Airvo features an integrated battery, high-pressure oxygen input and a broader flow range.
Optiflow nasal high flow therapy explained, what is it and how does it work?
F&P Solo™ Nasal is the world’s first AutoFit™ mask. It simplifies setup like no other, using AutoLock™ technology - stretch to fit, touch to adjust.
Airvo, F&P 950 and F&P 850 – this trio of humidification and respiratory support devices facilitate multiple respiratory therapies across the hospital
Join our global team. View and apply for jobs with us.
Get in touch with our team, find a distributor or send an enquire.
We value your privacy. Our websites and applications use cookies to function properly and securely.